Direct vitamin k antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation

Table 1 Breakdown of patients included in the study

	Male		Female		Overall
	Average %	SD	Average %	SD	Average %	SD
Population	N = 581		N = 676		N = 1,257
Age	76.55	9.47	80.01	8.48	78.41	9.11
Age groups
27–74 years	33.22		19.82		26.01
75–80 years	29.78		26.92		28.24
81–84 years	17.90		24.11		21.20
85–99 years	19.10		29.14		24.50
Visits*	13.93	6.58	14.22	6.51	14.08	6.54
Percentage of visits with incident*	19.11	18.93	19.35	18.53	19.24	18.71
INR	2.50	0.40	2.53	0.36	2.52	0.38
Average weekly dose of VKA (mg)	12.93	6.46	11.99	5.96	12.43	6.21
Patients participating in the study for over 5 months	N = 435		N = 509		N = 944
Age	76.37	9.27	79.41	8.32	78.01	8.90
Age groups
27–74 years	34.94		22.40		28.18
75–80 years	29.43		28.49		28.92
81–84 years	19.31		22.59		21.08
85–99 years	16.32		26.52		21.82
Visits*	16.59	5.03	16.78	4.98	16.69	5.00
Percentage of visits with incident*	15.88	13.71	17.17	14.24	16.58	14.01
INR	2.50	0.25	2.53	0.25	2.52	0.25
Average weekly dose of VKA (mg)	12.83	6.55	12.05	5.96	12.41	6.25

Note: Stars denote statistically significant differences between the sample and the population at 95% confidence.

ISSN: 1472-6963